The first patient has been dosed in Microbiotica’s Phase 1b first-in-human trial, COMPOSER-1, of MB310.

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment option. With Johnson & Johnson’s Tremfya now ...

Ulcerative colitis (UC) is a chronic gut inflammatory condition affecting the colon in humans. This study uses human samples as well as a mouse model of colitis induced by a chemical, DSS, to ...

Microscopic colitis diseases are unusual and possibly autoimmune. They are sometimes triggered by medications and treated ...

Researchers found that a chromosome 6 locus within the HLA region was significantly associated with severe vs less severe ulcerative colitis.

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that the first patient has been ...

P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis," published in the November 2024 issue of Gastroenterology by Hu et al. Since 2015, CT-P13, a ...

Abivax presents third quarter 2024 key financial information. PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – AB ...